Footnotes

[1] Explanatory Memorandum, p. 1.

[2] Explanatory Memorandum, p. 26.

[3] Explanatory Memorandum, p. 1.

[4] Explanatory Memorandum, p. 29.

[5] IPTA, Submission 1, pp. 5–6.

[6] IPTA, Submission 1, pp. 5–6.

[7] Dr O'Rourke, Proof Committee Hansard, 3 August 2006, p. 16.

[8] IP Australia, Responses to questions on notice, 7 August 2006, p. 11. See Appendix 3.

[9] Dr O'Rourke, Proof Committee Hansard, 3 August 2006, pp. 16–17.

[10] Dr O'Rourke, Proof Committee Hansard, 3 August 2006, p. 17.

[11] IP Australia, Responses to questions on notice, 7 August 2006, p. 11.

[12] Explanatory Memorandum, p. 1.

[13] Explanatory Memorandum, p. 37.

[14] IPTA, Submission 1, pp. 6–7.

[15] IP Australia, Responses to questions on notice, 7 August 2006, p. 12. See Appendix 3.

[16] Explanatory Memorandum, p. 39.

[17] Bills Digest, No. 159, 19 June 2006, p. 10.

[18] Explanatory Memorandum, p. 39.

[19] Intellectual Property and Competition Review Committee (IPCRC), Review of the Intellectual Property Legislation under the Competition Principles Agreement, 30 September 2000, p. 158.

[20] Explanatory Memorandum, p. 39.

[21] Explanatory Memorandum, p. 3.

[22] Explanatory Memorandum, p. 1.

[23] IPTA, Submission 1, p. 7.

[24] IPTA, Submission 1, p. 8.

[25] IPTA, Submission 1, p. 8.

[26] IPTA, Submission 1, pp. 8–9.

[27] Dr Thomas Faunce, Submission 7, pp. 5-6.

[28] IPTA, Submission 1, p. 9.

[29] GMiA, Submission 6, pp. 3–4.

[30] GMiA, Submission 6, p. 3.

[31] Second Reading Speech, The Hon. Mr Robert Baldwin MP, 30 March 2006.

[32] Bills Digest, No. 159, 19 June 2006, p. 6.

[33] Bills Digest, No. 159, 19 June 2006, p. 6.

[34] Explanatory Memorandum, p. 19.

[35] Explanatory Memorandum, p. 19.

[36] Explanatory Memorandum, p. 23.

[37] IPTA, Submission 1, p. 9.

[38] Nufarm, Submission 2, p. 1.

[39] Medicines Australia, Submission 4, p. 2.

[40] GMiA, Submission 6, p. 1.

[41] Bill, p. 23.

[42] IPTA, Submission 1, p. 9.

[43] Submission 4, p. 3.

[44] Submission 4, p. 5.

[45] Submission 4, p. 5.

[46] Submission 4 , p. 3.

[47] Evergreening – a description used by critics of the major drug companies of a strategy allegedly employed by brand-name drug companies to extend patent protection on their medicines and keep generic versions off the market.  Derived from http://en.wikipedia.org/wiki/Generic_drug

[48] Submission 6, p. 2.

[49] Dr Tom Faunce, Submission 7, p. 3.

[50] Dr Tom Faunce, Submission 7, p. 3. Dr Faunce's submission includes a useful and detailed discussion about evergreening.

[51] Submission 2, p. 1.

[52] Submission 2, p. 1

[53] Mr Lee, Senate Hansard Committee, p. 3.

[54] Mr Gallagher, Senate Hansard Committee, p. 3.

[55] Mr Pennifold, Senate Hansard Committee, pp. 10-11.

[56] Bills Digest, No. 159, 19 June 2006, p. 11.

[57] Explanatory Memorandum, p. 11.

[58] Bill Digest, No. 159, 19 June 2006, pp. 11-12.

[59] Bill Digest, No. 159, 19 June 2006, p. 12.

[60] Bills Digest, No. 159, 19 June 2006, p. 12.

[61] IPTA, Submission 1, p. 10.

[62] Australia-United States Free Trade Agreement, Article 17.9 Patents, paragraph 7A http://www.dfat.gov.au/trade/negotiations/us_fta/final-text/chapter_17.html [accessed 1 August 2006]

[63] Queensland University of Technology, Submission 3.

[64] QUT, Submission 3, p. 5.

[65] QUT, Submission 3, p. 6.

[66] QUT, Submission 3, p. 6.

[67]    NT Power Generation Pty Ltd v Power and Water Authority (2004) 219 CLR 90 at 122 per 

           McHugh ACJ, Gummow, Callinan and Heydon JJ.

[68] Proof Committee Hansard, 3 August 2006, p. 6.

[69] IP Australia, Responses to questions on notice, 7 August 2006, p. 7. (see Appendix 3)

[70] Proof Committee Hansard, 3 August 2006, p. 6.

[71] IP Australia, Responses to questions on notice, 7 August 2006, p. 8. (see Appendix 3)

[72] Proof Committee Hansard, 3 August 2006, p. 7.

[73] IP Australia, Responses to questions on notice, 7 August 2006, pp. 8-9. (see Appendix 3)

[74] Ms Catherine Macneil, Submission 5.

[75]   IP Australia, Responses to questions on notice, 7 August 2006, p. 14 (see Appendix 3)